Ví dụ về việc sử dụng Zoledronic trong Tiếng anh và bản dịch của chúng sang Tiếng việt
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Reclast and Zometa are two different brands of zoledronic acid.
With repeated use of zoledronic acid or other bisphosphonates.
Reclast and Zometa are two different brands of zoledronic acid.
The other half received zoledronic acid in addition to the standard treatment.
Zometa contains the same active substance as found in Aclasta(zoledronic acid).
Mọi người cũng dịch
The active substance in Aclasta, zoledronic acid, is a bisphosphonate.
Zoledronic acid injection is indicated for treatment of Paget's disease of bone in men and women.
Lower the risk of fractures, especially if zoledronic acid is not working.
In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis.
The principal pharmacologic action of zoledronic acid is inhibition of bone resorption.
On the day that zoledronic acid is given, you should eat normally and drink at least 2 glasses(500 mL or 2 cups) of water before and after receiving the medication.
In-vitro and ex-vivo studies showed low affinity of zoledronic acid for the cellular components of human blood.
The pharmacokinetics of zoledronic acid was not affected by age in patients with cancer and bone metastases whose age ranged from 38 years to 84 years.
The area under the plasma concentration versus time curve(AUC0-24h) of zoledronic acid was dose proportional from 2 to 16 mg.
You should know that zoledronic acid injection is available under the brand names Zometa and Reclast.
Treatment for prostate cancer that hasspread to the bones includes drugs such as zoledronic acid(Zometa) and denosumab(Xgeva).
Safety and effectiveness of zoledronic acid in pediatrics has not been established.
The average AUC0-24 in patients with normal renal function was 0.42 mg•h/L and the calculated AUC0-∞ for a patient with creatinine clearance of 75 mL/min was0.66 mg•h/L following a 4-mg dose of zoledronic acid injection.
The pharmacokinetics of zoledronic acid were not affected by age in patients with cancer and bone metastases who ranged in age from 38 years to 84 years.
These symptoms may begin during thefirst 3 days after you receive a dose of zoledronic acid injection and may last 3 to 14 days.
With an acute overdose of zoledronic acid, impaired renal function(including renal failure) and a change in electrolyte composition may occur.
A 2012 meta-analysisfound that denosumab was better than placebo, zoledronic acid and pamidronate in reducing the risk of fractures in those with cancer.[6].
If you take zoledronic acid, report any pain, swelling, or infection of the jaw to your doctor, and avoid invasive dental procedures such as tooth extractions.
Limited pharmacokinetic data are available for zoledronic acid injection in patients with severe renal impairment(creatinine clearance less than 30 mL/min).
Zoledronic acid(Zometa®): Zoledronic acid is a bisphosphonate drug that can effectively prevent loss of bone that occurs from cancer that has spread to the bones thereby reducing the risk of fractures, and decreasing pain.
The accumulation of zoledronic acid measured over three cycles was low, with mean AUC0-24h ratios for cycles 2 and 3 versus 1 of 1.13± 0.30 and 1.16± 0.36, respectively.
Zoledronic acid, also known as zoledronate, is a medication used to treat a number of bone diseases.[2] These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, and Paget's disease of bone.[2] It is given by injection into a vein.
ASA allergy: Although not reported with zoledronic acid, people who are allergic to acetylsalicylic acid(ASA) have had breathing problems after using other medications in the same family as zoledronic acid.
Zoledronic acid was patented in 1986 and approved for medical use in the United States in 2001.[1][3] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] The wholesale cost in the developing world is between 5.73 USD and 26.80 USD per vial.[5] In the United Kingdom, as of 2015, a dose costs the NHS about 220 pounds.
Following an intravenous dose of 20 nCi 14C-zoledronic acid in a patient with cancer and bone metastases, only a single radioactive species with chromatographic properties identical to those of parent drug was recovered in urine,which suggests that zoledronic acid is not metabolized.